Nasal Spray Influenza Vaccine Market Anticipated To Witness Robust Growth, Surpassing 2.43 Billion By 2029

Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.

What Is the Current Nasal Spray Influenza Vaccine Market Size and Its Estimated Growth Rate?
The market size for the nasal spray influenza vaccine has been witnessing a swift surge in recent years. The market, which will rise from $1.31 billion in 2024, is expected to reach $1.49 billion in 2025, marking a compound annual growth rate (CAGR) of 13.2%. The escalation during the past period has been influenced by factors such as heightened vaccine availability, increased awareness regarding flu prevention, amplified focus on vaccinations for children, augmented vaccination rates, and growing preference for vaccines that don't require needles.

In the coming years, a rapid expansion is expected in the market size of the nasal spray influenza vaccine, predicted to reach $2.43 billion by 2029, growing at a compound annual growth rate (CAGR) of 13.1%. Factors contributing to this growth during the forecasted period include an escalating demand for convenient immunization methods, an increase in seasonal influenza cases, enhanced government support and initiatives, projected growth in aged and high-risk populations, and its rising prevalence in TH*Care environments. The forecast period will also see innovative trends such as advancements in vaccine delivery systems, the incorporation of mucosal immunity strategies, technological evolution in viral vector platforms, progress in cold-chain technology, and the integration of mRNA technology.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/customise?id=24326&type=smp

How Are Emerging Segments Shaping the Nasal Spray Influenza Vaccine Market Landscape?
The nasal spray influenza vaccine market covered in this report is segmented -

1) By Type: Live Attenuated Influenza Vaccine (LAIV), Inactivated Influenza Vaccine
2) By Administration Method: Single-Dose Administration, Multi-Dose Administration
3) By Age Group: Pediatric, Adult, Geriatric
4) By Distribution Channel: Hospitals, Clinics, Pharmacies, Online Stores, Other Distribution Channels
5) By End User: TH*Care Providers, Individuals, Government Health Departments, Pharmaceutical Companies

Subsegments:

1) By Live Attenuated Influenza Vaccine (LAIV): Trivalent Live Attenuated Influenza Vaccine (Trivalent LAIV), Quadrivalent Live Attenuated Influenza Vaccine (Quadrivalent LAIV)
2) By Inactivated Influenza Vaccine: Whole Virus Inactivated Vaccine, Split Virus Inactivated Vaccine, Subunit Inactivated Vaccine, Adjuvanted Inactivated Vaccine, High-Dose Inactivated Vaccine

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24326&type=smp

Which Growth Factors Are Influencing Nasal Spray Influenza Vaccine Market Expansion?
The surge in influenza occurrences is anticipated to boost the expansion of the nasal spray influenza vaccine market. Influenza is a highly infectious viral disease that mainly impacts the respiratory system, leading to symptoms such as fever, cough, sore throat, body pains, and tiredness. The frequent genetic alterations of the influenza virus, which help it dodge existing immunity and proliferate quickly among people, primarily contribute to the rising prevalence of influenza. The nasal spray influenza vaccine aids in protecting against influenza by introducing a mild form of the virus directly into the nasal passages, triggering an immune reaction where the virus typically invades the body. For example, the UK Health Security Agency confirmed in June 2024 that from week 40 of 2022 to week 15 of 2023, 108 NHS trusts in England reported 1,681 influenza-related critical care admissions. This is significantly higher than the preceding season which witnessed only 182 admissions reported by 114 trusts, growing to 316 admissions by week 39 of 2022. Hence, the escalating prevalence of influenza is fueling the growth of the nasal spray influenza vaccine market.

Who Are the Dominant Players Across Different Nasal Spray Influenza Vaccine Market Segments?
Major companies operating in the nasal spray influenza vaccine market are Sanofi Pasteur SA, AstraZeneca PLC, GSK plc, Moderna Inc., CSL Limited, Sinovac Biotech Ltd., Emergent BioSolutions Inc., Serum Institute of India Pvt. Ltd., Beijing Wantai Biological Pharmacy Enterprise Co. Ltd., NPO Microgen JSC, Changchun BCHT Biotechnology Co. Ltd., Mitsubishi Tanabe Pharma Corporation, FluGen Inc., BioDiem Ltd, Starpharma Holdings Limited, Codagenix Inc., Nobilon International B.V., KM Biologics Co. Ltd., Altimmune Inc., Mylab Discovery Solutions Private Limited

What Are the Major Trends Shaping the Nasal Spray Influenza Vaccine Market?
Leading enterprises in the nasal spray influenza vaccine market are concentrating on the creation of innovative formulations like live attenuated influenza vaccine to heighten immune response and foster patient adherence. Live attenuated influenza vaccine (LAIV) is a type of flu vaccine, made using live but weakened flu viruses. It bolsters influenza prevention by triggering the immune system to generate antibodies, offering protection without causing illness. It also aids in arming the body better against future flu infections through both local and systemic immunity. For example, in September 2024, the US Food and Drug Administration granted approval to AstraZeneca Plc, a pharmaceutical firm based in the UK, for the usage of FluMist, a live attenuated influenza vaccine (LAIV). This vaccine can be self-administered by adults up to the age of 49 or given by caregivers to children aged 2 to 17, making it the first and only flu vaccine approved for self or caregiver-usage within the United States. The approval was granted based on exhaustive usability studies that proved the ability of users to correctly self-administer the vaccine, with all participants successfully delivering a full dose following the instructions provided.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/nasal-spray-influenza-vaccine-global-market-report

Which Geographic Regions Are Expected to Dominate the Nasal Spray Influenza Vaccine Market in the Coming Years?
North America was the largest region in the nasal spray influenza vaccine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nasal spray influenza vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Nasal Spray Influenza Vaccine Market?
2. What is the CAGR expected in the Nasal Spray Influenza Vaccine Market?
3. What Are the Key Innovations Transforming the Nasal Spray Influenza Vaccine Industry?
4. Which Region Is Leading the Nasal Spray Influenza Vaccine Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.